Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Piramal Pharma Limited, is an unlisted public company incorporated on 04 March, 2020. It is classified as a public limited company and is located in Mumbai City, Maharashtra. It's authorized share capital is INR 3,000.00 cr and the total paid-up capital is INR 1,322.95 cr.
Piramal Pharma Limited's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has decreased by 75.45% over the previous year. At the same time, it's book networth has increased by 3.84%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
11.25%
-75.45%
-79.74%
3.84%
47.73%
11.57%
-3.44
-10.01
-8.5
-5.45
-14.59
0.09
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(44)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO |
| Networth | |||
| Borrowings | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO |
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO |
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO |
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| Solvency + | |||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||
| Current Ratio | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO |
| Performance | |||
| Gross Margin | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO |
| Return + | |||
| Return on Equity | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||
| Days Payable | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO |
| Working Capital | |||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Ramadorai Subramanian
Shareholder
|
00000002 | 4 years |
| Director | Sridhar Gorthi | 00035824 | 3 years |
| Director | Jairaj Manohar Purandare | 00159886 | 4 years |
| Whole-time Director | Nandini Ajay Piramal
Shareholder
|
00286092 | 5 years |
| Director | Neeraj Bharadwaj | 01314963 | 4 years |
| Director | Vibha Paul Rishi | 05180796 | 2 years |
| CFO | Vivek Valsaraj
Shareholder
|
<HIDDEN> | 4 years |
| Whole-time Director | Vivek Valsaraj
Shareholder
|
06970246 | 3 years |
| Whole-time Director | Peter D Deyoung
Shareholder
|
07152550 | 5 years |
| Director | Peter Andrew Stevenson | 09544706 | 3 years |
| Director | Nathalie Ann Leitch | 09557042 | 3 years |
| CS | Tanya Smiley Dcosta
Shareholder
|
<HIDDEN> | 4 years |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Piramal Critical Care Deutschland GmbH | Germany | - | - |
| Piramal Critical Care Italia, S.P.A | Italy | - | - |
| Piramal Critical Care Limited | United Kingdom | - | - |
| Piramal Healthcare (Canada) Limited | Canada | - | - |
| Piramal Healthcare (UK) Limited | United Kingdom | - | - |
| Piramal Healtchare Pension Trustees Limited | United Kingdom | - | - |
| Piramal Critical Care South Africa (Pty) Ltd | South Africa | - | - |
| Piramal Dutch Holdings N.V. | Netherlands | - | - |
| Piramal Healthcare Inc. | United States | - | - |
| Piramal Critical Care, Inc. | United States | - | - |
| Piramal Pharma Inc. | United States | - | - |
| Piramal Pharma Solutions Inc. | United States | - | - |
| PEL Pharma Inc. | United States | - | - |
| Ash Stevens LLC | United States | - | - |
| Piramal Critical Care B.V. | Netherlands | - | - |
| Piramal Critical Care Pty Limited | Australia | - | - |
| PEL Healthcare LLC | United States | - | - |
| Piramal Pharma Solutions (Dutch) B.V. | Netherlands | - | - |
| Piramal Pharma Japan GK | Japan | - | - |
The incorporation date of PIRAMAL PHARMA LIMITED is 04 March, 2020
The authorized share capital of PIRAMAL PHARMA LIMITED is INR ₹ 3,000.0 Cr.
The paid-up capital of PIRAMAL PHARMA LIMITED is INR ₹ 1,322.9 Cr.
The registered address of PIRAMAL PHARMA LIMITED is Gr. Flr., Piramal Ananta, Agastya Corp. Park, Kamani Junct ion, LBS Marg, Kurla MUMBAI Mumbai City Maharashtra - 400070
The CIN number of PIRAMAL PHARMA LIMITED is U24297MH2020PLC338592.
Expand
Delete
Collapse
See
details
